治験一覧
8,963 件中 841〜860 件を表示
2型糖尿病患者における薬剤NNC0487-0111の異なる投与量による血糖値低下効果を比較した研究
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
特別使用 - Wegovy®の長期使用に関する結果監視
The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor. The study will last for about 4 years. Participant will be in the study for about 2 years (104 weeks).
中等度から重度のシェーグレン病におけるニポカリマブ
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
18歳から65歳までのアルコール関連肝疾患の成人患者を対象に、GSK4532990とプラセボを比較した安全性と有効性を検討する試験
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
T細胞リンパ腫およびCLL/SLLに対するONO-4685単剤療法の忍容性と安全性を調査する第I相試験
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
日本における乾癬性関節炎患者の生物学的製剤治療継続性：診療報酬請求データベースを用いた後向きコホート研究
This study was a retrospective non-interventional cohort study with secondary use of data from the Medical Data Vision (MDV) hospital-based database. The study setting was defined as follows: * The inclusion period covered 01 February 2015 to 30 September 2020. * The study period covered 01 August 2014 to 30 September 2021 inclusive. * The index date was defined as the date of the first prescription of secukinumab or adalimumab within the inclusion period. * The pre-index period was defined as the 6-month period before the index date (exclusive). * Patients were followed until death, discontinuation of treatments of interest or end of the study period, whichever occurred first.
BI 1815368の様々な投与量に対する耐性および健康な日本人男性の体内へのBI 1815368の取り込みを検証する研究
The main objectives of this trial are to investigate safety, tolerability. pharmacokinetics (PK), and pharmacodynamics of BI 1815368 in healthy Japanese male subjects following administration of single rising doses or multiple doses.
FINERODと呼ばれる観察研究は、フィネレノン治療薬の使用について、それが実際の状況でどれほど安全でどれほど効果的であるかなど、より詳しく知るためのものです。
This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied. The participants in this study are already receiving the study treatment finerenone as part of their regular care from their doctors. In observational studies, only observations are made without specified advice or interventions. CKD is a long-term progressive decrease in the kidneys' ability to work properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough. The resulting high blood sugar levels can cause damage to the kidneys. CKD often occurs together with T2D or as a consequence of T2D. Finerenone works by blocking certain proteins, called mineralocorticoid receptors. By doing this, it may reduce damage to kidneys, heart and blood vessels. Finerenone was recently approved in the US and is now available for doctors to prescribe to people with CKD together with T2D. Consequently, there is a need to collect more information about how finerenone is used, its safety and how well it works under real-world conditions. The main purpose of this study is to collect and describe the characteristics of people with CKD and T2D who are receiving initiate finerenone treatment as prescribed by their doctors. To do this, the researchers will collect general information of the participants such as age or gender and data on kidney function and possible heart problems. The researchers will also collect data on any other disease or medical condition in the participants and on other medications used while taking finerenone. The data will come from a network of commercial electronic health records (EHRs) and national claims data in the United States and in Asia. They cover the period from July 1st, 2021 until the latest data cut available for each dataset. Only already available data is collected and studied. There are no required visits or tests in this study.
固形腫瘍患者におけるGSK4418959単独または他の抗癌剤との併用投与の安全性、薬物動態、および予備的有効性を調査する試験
固形腫瘍は、体の様々な部位に発生する可能性のある異常な組織の塊です。本研究で対象となる腫瘍は、特定の遺伝的特徴を有しており、それにより悪性度が高まり、治療が困難になる場合があります。本研究では、GSK4418959単独投与、またはPD-1阻害薬との併用投与が腫瘍のサイズを縮小させるか、安全性と忍容性が良好であるか、そして体内の試験薬の量が時間の経過とともにどのように減少するかを検証します。
大腸がん患者に対する第一選択治療としてのONO-7913、ONO-4538および標準治療の比較研究
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer
レカネマブを投与された早期アルツハイマー病患者を対象とした市販後調査
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
MOONRAY-01：KRAS G12D変異固形腫瘍患者を対象としたLY3962673の試験
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
タフィンラー/メキニストの特別医薬品使用成績調査
This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.
AZD0901と、Claudin18.2を発現する進行または転移性胃癌または胃食道接合部腺癌の二次治療以降の参加者における治験担当医の選択による治療法との比較
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
肥満または過体重で、少なくとも1つの体重関連合併症を有する参加者を対象とした研究
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
予後不良卵巣癌患者におけるSALVage週1回投与高密度療法による化学療法量および投与スケジュールの調整の有用性（腫瘍の化学感受性不良および不完全な腫瘍摘出手術に基づく）
SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the continuation of the standard regimen.
PCNSLに対するONO-4059とR-MPVの併用療法の忍容性、安全性、薬物動態、および有効性を評価する第I相試験
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.
線維筋痛症患者におけるONO-1110の臨床試験
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Fibromyalgia
結合組織疾患を伴う間質性肺疾患の成人患者におけるベリムマブの有効性と安全性に関する研究
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
これは、PD-L1レベルが高い非小細胞肺がん患者において、研究薬シグボタツグ・ベドチンとペンブロリズマブの併用がどのように作用するかを調べるための研究です。
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab. Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.